Surrogate markers of antitumor responses: in vitro activation of T cells by autologous tumor peptides.

Abstract

The increasing ability to augment antitumor immunity in model systems has led to increased numbers of clinical trials. However, progress in detecting immune responses by patients against autologous tumors has been slow. Although a considerable number of tumor antigens, as well as peptides derived from them, and the MHC determinants together with which they… (More)

Topics

2 Figures and Tables

Cite this paper

@article{Zier2001SurrogateMO, title={Surrogate markers of antitumor responses: in vitro activation of T cells by autologous tumor peptides.}, author={Karen S. Zier and Jeanne M. Maddux and K. Johnson and M. Sung and John P. Mandeli and Lara Eisenbach and Martin A Schwartz}, journal={Clinical cancer research : an official journal of the American Association for Cancer Research}, year={2001}, volume={7 3 Suppl}, pages={818s-821s} }